DUBLIN and BAGSVÆRD, Denmark, Sept. 16, 2019 (GLOBE NEWSWIRE) — Medtronic plc (MDT), and Novo Nordisk A/S today announced a collaboration that will develop solutions to integrate insulin dosing data from future Novo Nordisk smart insulin pens into Continuous Glucose Monitoring (CGM) devices from Medtronic, such as the Guardian™ Connect system. People with diabetes spend an average of one hour a day on self-care, amounting to a full two years devoted exclusively to their disease over their lifetime.1,2This new, non-exclusive collaboration reflects both companies′commitment to making diabetes management easier by integrating key health technologies.

source https://finance.yahoo.com/news/medtronic-novo-nordisk-enter-agreement-070000819.html?.tsrc=rss